Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity

被引:360
作者
Parman, T
Wiley, MJ
Wells, PG
机构
[1] Univ Toronto, Fac Pharm, Toronto, ON M5S, Canada
[2] Univ Toronto, Dept Pharmacol, Toronto, ON M5S, Canada
[3] Univ Toronto, Dept Anat & Cell Biol, Toronto, ON M5S, Canada
基金
英国医学研究理事会;
关键词
D O I
10.1038/8466
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The sedative drug thalidomide ([+]-alpha-phthalimidoglutarimide), once abandoned for causing birth defects in humans', has found new therapeutic license in leprosy and other diseases, with renewed teratological consequences(2). Although the mechanism of teratogenesis(3) and determinants of risk remain unclear, related teratogenic xenobiotics are bioactivated by embryonic prostaglandin H synthase (PHS) to a free-radical intermediates that produce reactive oxygen species (ROS), which cause oxidative damage to DNA and other cellular macromolecules(4,5) Similarly, thalidomide is bioactivated by horseradish peroxidase, and oxidizes DNA(6) and glutathione(7), indicating free radical-mediated oxidative stress. Furthermore, thalidomide teratogenicity in rabbits is reduced by the PHS inhibitor acetylsalicylic acid, indicating PHS-catalyzed bioactivation(8). Here, we show in rabbits that thalidomide initiates embryonic DNA oxidation and teratogenicity, both of which are abolished by pre-treatment with the free radical spin trapping agent alpha-phenyl-N-t-butylnitrone (PBN). In contrast, in mice, a species resistant to thalidomide teratogenicity, thalidomide does not enhance DNA oxidation, even at a dose 300% higher than that used in rabbits, providing insight into an embryonic determinant of species-dependent susceptibility. In addition to their therapeutic implications, these results constitute direct evidence that the teratogenicity of thalidomide may involve free radical-mediated oxidative damage to embryonic cellular macromolecules.
引用
收藏
页码:582 / 585
页数:4
相关论文
共 28 条
[1]  
ARLEN R R, 1990, FASEB Journal, V4, pA608
[2]  
Arlen RR, 1996, J PHARMACOL EXP THER, V277, P1649
[3]   Thalidomide: lack of mutagenic activity across phyla and genetic endpoints [J].
Ashby, J ;
Tinwell, H ;
Callander, RD ;
Kimber, I ;
Clay, P ;
Galloway, SM ;
Hill, RB ;
Greenwood, SK ;
Gaulden, ME ;
Ferguson, MJ ;
Vogel, E ;
Nivard, M ;
Parry, JM ;
Williamson, J .
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 1997, 396 (1-2) :45-64
[4]   TERATOGEN METABOLISM - THALIDOMIDE ACTIVATION IS MEDIATED BY CYTOCHROME-P-450 [J].
BRAUN, AG ;
HARDING, FA ;
WEINREB, SL .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1986, 82 (01) :175-179
[5]  
Castilla EE, 1996, TERATOLOGY, V54, P273, DOI 10.1002/(SICI)1096-9926(199612)54:6<273::AID-TERA1>3.0.CO
[6]  
2-#
[7]  
CHENG KC, 1992, J BIOL CHEM, V267, P166
[8]   THALIDOMIDE TERATOGENESIS - EVIDENCE FOR A TOXIC ARENE OXIDE METABOLITE [J].
GORDON, GB ;
SPIELBERG, SP ;
BLAKE, DA ;
BALASUBRAMANIAN, V .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (04) :2545-2548
[9]   INDUCTION OF MORPHOLOGICAL-DIFFERENTIATION IN THE HUMAN LEUKEMIC-CELL LINE K562 BY EXPOSURE TO THALIDOMIDE METABOLITES [J].
HATFILL, SJ ;
FESTER, ED ;
DEBEER, DP ;
BOHM, L .
LEUKEMIA RESEARCH, 1991, 15 (2-3) :129-136
[10]  
Huang PHT, 1997, TERATOGEN CARCIN MUT, V17, P1, DOI 10.1002/(SICI)1520-6866(1997)17:1<1::AID-TCM2>3.0.CO